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Abstract
Background: Onchocerca volvulus is the causative agent of onchocerciasis, or ‘‘river blindness’’. Ivermectin has been used for
mass treatment of onchocerciasis for up to 18 years, and recently there have been reports of poor parasitological responses
to the drug. Should ivermectin resistance be developing, it would have a genetic basis. We monitored genetic changes in
parasites obtained from the same patients before use of ivermectin and following different levels of ivermectin exposure.
Methods and Findings: O. volvulus adult worms were obtained from 73 patients before exposure to ivermectin and in the
same patients following three years of annual or three-monthly treatment at 150 mg/kg or 800 mg/kg. Genotype frequencies
were determined in b-tubulin, a gene previously found to be linked to ivermectin selection and resistance in parasitic
nematodes. Such frequencies were also determined in two other genes, heat shock protein 60 and acidic ribosomal protein,
not known to be linked to ivermectin effects. In addition, we investigated the relationship between b-tubulin genotype and
female parasite fertility. We found a significant selection for b-tubulin heterozygotes in female worms. There was no
significant selection for the two other genes. Quarterly ivermectin treatment over three years reduced the frequency of the
b-tubulin ‘‘aa’’ homozygotes from 68.6% to 25.6%, while the ‘‘ab’’ heterozygotes increased from 20.9% to 69.2% in the
female parasites. The female worms that were homozygous at the b-tubulin locus were more fertile than the heterozygous
female worms before treatment (67% versus 37%; p=0.003) and twelve months after the last dose of ivermectin in the
groups treated annually (60% versus 17%; p,0.001). Differences in fertility between heterozygous and homozygous worms
were less apparent three months after the last treatment in the groups treated three-monthly.
Conclusions: The results indicate that ivermectin is causing genetic selection on O. volvulus. This genetic selection is
associated with a lower reproductive rate in the female parasites. We hypothesize that this genetic selection indicates that
a population of O. volvulus, which is more tolerant to ivermectin, is being selected. This selection could have implications for
the development of ivermectin resistance in O. volvulus and for the ongoing onchocerciasis control programmes.
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Introduction
Onchocerca volvulus is the filarial nematode, transmitted by
Simulium flies, that causes human onchocerciasis, or ‘‘river
blindness’’. It is estimated that 37 million people, mostly in Africa,
are infected with this worm [1]. At present, ivermectin (IVM,
Mectizan) is the only safe drug available for mass treatment of
onchocerciasis. IVM, administered at the standard dose of
150 mg/kg, has a rapid effect on the embryonic stage of the
parasite, the microfilariae (mf), which cause most of the ocular and
cutaneous manifestations of the disease. As a result of this
microfilaricidal effect, the skin microfilarial loads decrease by
95–99% within one month after treatment. The drug also blocks
the production of new mf by the adult female worms, who only
resume mf release 3–6 months after treatment. This ‘‘embryostatic
effect’’ of IVM explains why the mf loads remain at very low levels
for up to one year. Furthermore, IVM treatments repeated at 1- to
3-monthly intervals have some, though moderate, effect on the
longevity of the adult worms (‘‘macrofilaricidal effect’’) [2,3].
The drug, when given repeatedly, is therefore acting on at least
three components of parasite fitness: reproduction, microfilarial
survival and adult parasite lifespan, which together affect
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macrofilaricidal effect of the drug, treatments must be repeated
and sustained. Endemic communities in Africa receive annual
IVM treatment, while those of Latin America receive semi-annual
treatments. To date, more than 400 million treatments have been
distributed in Africa [4], with some individuals having received up
to 18 annual treatments.
Due to this enormous drug pressure on the parasite, there is
a risk of resistance of O. volvulus to the drug [5–7]. This concern is
justified by reports of suboptimal responses to IVM from Sudan
[8] and Ghana [9,10], although in the former report reduced
immune responsiveness in some of the treated people has been
suggested as a possible explanation for the suboptimal responses to
IVM. And in the study in Ghana the poor responses have been
attributed to the parasites, with adult female worms resuming
microfilarial production earlier after treatment than classically
described. More recently, another report in Ghana [11] shows the
first unequivocal parasitological and epidemiological evidence of
ivermectin resistance in O. volvulus populations.
In addition to this evidence of IVM resistance, changes in the
genetic structure of O. volvulus populations, associated with IVM
treatments, have been observed in parasites from Ghana [12–16].
These changes occurred particularly on the b-tubulin gene [16,17],
which has been associated with IVM resistance in the sheep intesti-
nal nematode Haemonchus contortus [17]. However, in these previous
studies, O. volvulus from IVM-naı ¨ve and -treated human populations
were collected from different individuals in different communities.
It is important to assess whether the genetic changes reported in
O. volvulus are associated with a reduced response to IVM in any of
the three effects of IVM on parasite fitness, described above.
Furthermore, to eliminate the possibility that differences in
genotype frequencies between IVM-naı ¨ve and -treated popula-
tions could be due to geographical effects, due to separate
individuals and communities being sampled, it is important to
assess whether changes in genetic frequency could occur in
parasites collected from the same individuals before and after
exposure to IVM. Genetic changes clearly associated with
treatment, which could not possibly be associated with other
covariates, would provide unequivocal evidence of genetic
selection by IVM on O. volvulus. Such treatment-induced selection
would be heritable. Heritable genetic changes that could reduce
the susceptibility of O. volvulus to any of the effects of IVM on the
parasite could have long-term consequences for the control of
onchocerciasis because there is currently no alternative drug
available for mass treatment of this disease.
In a previous study [18], we reported that in an IVM-naı ¨ve O.
volvulus population from Cameroon, adult female worms present-
ing a homozygous genotype for b-tubulin were more fertile than
adult worms that were heterozygous at this locus. In the present
study, we have analyzed genetic characteristics (b-tubulin gene and
two control genes, heat shock protein 60 (hsp60) and acidic ribosomal
protein (ARP)) and phenotypic characteristics (female worm fertility)
of parasites collected, in the same individuals, before and after 4 or
13 IVM treatments over a three-year period. These treatments
were administered as part of a clinical trial conducted in Central
Cameroon. The main objective of this trial was to assess the effects
of different regimens of IVM treatment on the mortality of O.
volvulus adult worms, and the results of this phase have been
published elsewhere [3]. In the second phase, results of which are
presented in this paper, we evaluated whether repeated treatment
with IVM led to (a) genetic changes in the adult worm population
and (b) any modification of the relationship between b-tubulin
genotype of the female worms and their reproductive status.
Methods
Study Area, Study Design and Selection of Patients
The study was carried out in the Mbam Valley, a region hyper-
endemic for onchocerciasis, located in the Central province of
Cameroon, where no IVM had been distributed at the beginning
of the study and where no vector control activities have ever been
performed. In this area, before the introduction of IVM, the
intensity of infection in the population, as expressed by the
Community Microfilarial Loads (CMFL) [19] ranged between 10
and 114 mf per skin snip (mf/ss) [3]. The full details of the clinical
trial, which was approved by the Cameroonian Ministry of Public
Health andbyMerckand Co.,themanufacturerofIVM(Mectizan),
have been published elsewhere [3]. The study also subsequently
received approval from the institutional review board of McGill
University. Briefly, 657 individuals were selected using the following
inclusion criteria: men between 18 and 60 yearsold,with at least two
palpable nodules during the preliminary examination but otherwise
ingood health,who had not received anyfilaricidal treatment within
the five previous years, and who agreed to participate in the trial by
signing an informed consent form. These patients were randomly
allocated to one of the four following IVM treatment groups:
150 mg/kgbodyweight/year(standardgroup;group1);150 mg/kg/
three-monthly (group 2); 800 mg/kg/year (group 3); and 800 mg/
kg/three-monthly (group 4). Over the three-year study period,
patients received either 4 or 13 IVM treatments.
Collection of Nodules and Parasitological Examination
In order to assess the macrofilaricidal effect of IVM on O.
volvulus, adult worms were collected, by nodulectomy, at the outset
of the trial (before the first IVM dose was administered) and once
again after three years of treatment in the four different treatment
groups described above. The protocol used for parasite collection
was identical for the two rounds of nodulectomy. Just before each
round of nodulectomy, each person was carefully examined and all
the sites on their body where a nodule or a group of nodules was
palpable were recorded on a body chart. Subsequently, one of the
sites was selected at random and all the nodules located at this site
were removed from each person. The site selected for the second
Author Summary
Onchocerca volvulus is the causative agent of onchocerci-
asis, or ‘‘river blindness’’. Ivermectin has been used for
mass treatment of onchocerciasis for up to 18 years, and
recently there have been reports of poor parasitological
responses to the drug and evidence of drug resistance.
Drug resistance has a genetic basis. In this study, genetic
changes in b-tubulin, a gene associated with ivermectin
resistance in nematodes, were seen in parasites obtained
from the patients exposed to repeated ivermectin
treatment compared with parasites obtained from the
same patients before any exposure to ivermectin. Further-
more, the extent of the genetic changes was dependent
on the level of ivermectin treatment exposure. This genetic
selection was associated with a lower reproductive rate in
the female parasites. The data indicates that this genetic
selection is for a population of O. volvulus that is more
tolerant to ivermectin. This selection could have implica-
tions for the development of ivermectin resistance in O.
volvulus and for the ongoing onchocerciasis control
programmes. Monitoring for the possible development
and spread of ivermectin resistance, as part of the control
programmes, should be implemented so that any foci of
resistant parasites can be treated by alternative control
measures.
Ivermectin selection in O. volvulus
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so that the worms collected at that time had probably been
subjected to the IVM treatments administered over the previous
three years. Just after the nodulectomy, all the nodules collected
were immersed in fixative (70% ethanol, 20% water, 10%
glycerol). One of the nodules was used for histological examina-
tion, as previously described [3], to evaluate the status of the
worms. Any additional nodules (‘‘extra nodule’’) from the excision
site were stored in the fixative at room temperature and available
for genotyping and phenotyping.
Selection of Nodules for Genotyping and Phenotyping
Of the 657 individuals selected before treatment, 290 had more
than one nodule at the first nodulectomy site, and thus at least one
‘‘extra nodule’’ available after the histological examination.
Similarly, of the 541 patients present at the second round of
nodulectomy (following three years of treatment), 156 had at least
one extra nodule available. Patients included in the present study
were selected taking into account our objectives, which were to
assess the genotypes of three polymorphic genes, including b-
tubulin, in the adult worms, and any relationship between the
genotype of female parasites and their reproductive status, before
and after IVM treatment. To make the comparison more sensitive,
we performed the genotyping and the phenotyping only on
parasites obtained from those people for whom ‘‘extra nodules’’,
containing at least one adult worm, had been collected at both
nodulectomy rounds (pre-treatment and after three years of
repeated treatments). The total numbers of individuals who met
these inclusion criteria were 18 in group 1, 16 in group 2, 22 in
group 3 and 17 in group 4. Thus, the analyses were performed on
the nodules collected from 73 individuals.
Procedure for Phenotyping the Female Reproductive Status
This procedure has been described previously [18]. In 2002, the
nodules were washed with phosphate buffered saline (PBS) for
24 h with regular changes of medium in order to remove all
residues of fixative. The nodules were then digested in collagenase
[20]. Worms were collected and stored individually in labelled
Eppendorf tubes, which were frozen at 280uC. Each female worm
was phenotyped by microscopical examination of its reproductive
status in terms of the presence of mf and embryos. Three
phenotypes were defined: (a) non-fertile females, i.e. worms with
empty reproductive organs, (b) females with low fertility, in which
the reproductive organs contained only a few embryos, but no mf,
and (c) fully fertile females, in which the reproductive organs were
full of mf and embryos.
Procedure for Genotyping
After the phenotyping, each worm was disrupted and its DNA
was extracted using a Dneasy kit (Qiagen Inc., Mississauga,
Canada). Heat shock protein 60 (hsp60) (GenBank, AF121264), which
is a molecular chaperone that participates in the folding of
proteins, was chosen as a control gene. It was known to be
polymorphic and previously found not to be selected by IVM
treatment in O. volvulus [16]. Two polymorphs (‘‘A’’ and ‘‘G’’) were
found in the hsp60 gene partial sequence analyzed. The region
analyzed started at position 214 on the cDNA and included
100 bp in the exon, followed by 276 bp in the intron. The A/G
polymorphism was located in the intron region. The fragment of
376 bp was amplified by PCR from individual adult worms with
the primers 59CAA TCA TGG GGA AGT CCA AAG 39 and
59CTC AAA ACC TTC CTT TGC AAT 39 at Tm=53uC. PCR
products were sequenced with the hsp60 anti-sense primer using
the 3730XL DNA Analyzer system (McGill University/Genome
Quebec Innovation Centre). Platinum Taq DNA polymerase High
Fidelity (Invitrogen) was used in the PCR reaction to avoid
introduction of error during amplification. Each individual
chromatogram was analyzed with Sequencher 4.7 software (Gene
Codes Corporation, Ann Arbor, MI, USA), to detect the
homozygotes AA and GG and the heterozygotes AG.
The acidic ribosomal protein (ARP) gene (GenBank, AI130565),
which is involved in protein synthesis, was chosen as a second
control because it was expected to be polymorphic [21] and not
known to be sensitive to IVM treatment. Two polymorphs (‘‘C’’
and ‘‘T’’) were found in the acidic ribosomal protein gene partial
sequence analyzed. The region of interest was from 1270 bp to
1488 bp of the complete gene. It was amplified by PCR from
individual adult worms with the primers 59 TGA AAA ACT GCT
ACC GCA TA 39 and 59 AAA TTT TCG TTG GAA TTT GC 39
at Tm=54uC. PCR products were analyzed by restriction fragment
length polymorphism, based on C/T polymorphism apparent in the
EST database, using the restriction enzyme Mnl 1 for 2 hours, and
subjected to electrophoresis on a 12% polyacrylamide gel (39:1) for
2 hours at 130 V, stained with ethidium bromide and visualized
using an ABI Imager (Bio-Rad, Hercules, CA, USA).
Two alleles (‘‘a’’ and ‘‘b’’) have been described for b-tubulin [16].
These two alleles have three single nucleotide polymorphisms in
an exon region. These differences lead to changes in three amino
acids in the putative protein sequence. The worms were genotyped
individually for b-tubulin (GenBank, F019886) by PCR amplifica-
tion followed by amplicon length analysis [17].
Statistical Analysis
The aim of the analysis was to assess whether a variety of
covariates related to the worm, nodule or patient characteristics
were associated with three different dependent variables: (a) the
inability to genotype some of the worms from the preserved
nodules; (b) the frequency of the various polymorphs analyzed;
and (c) the degree of fertility of the worm. We considered the five
following covariates: the age of the patient at the outset of the trial
(continuous variable); the CMFL in the village of residence of the
patient, defined in four categories: 10–40, 41–60, 61–70, and
71–114 mf/ss; the treatment group (for analysis of the worms
collected post-treatment: 150 mg/kg/year, 150 mg/kg/three-
monthly, 800 mg/kg/year, and 800 mg/kg/three-monthly); the
total number of females in the nodule; and the total number of
palpable nodules on the patient at the outset of the trial. In addition,
we also assessed the degree of fertility in relation to the genotype of
the worms and to the total number of males in the nodule.
Study of Possible Bias in Female Worms That Could Not
Be Genotyped
The procedure for genotyping the worms failed with a significant
number of worms obtained from the nodules that had been
preserved at room temperature for 5 to 8 years. To test whether
this inability to genotype some worms could be explained by
sampling biases, we assessed, using multivariate logistic regression,
whether the success in genotyping the worm (genotyped vs. non-
genotyped status) was associated with one or the other of the
possible covariates quoted above. All regressions analyses were
performed using Stata v9.0 (Stata Corporation, TX, USA), where
parameters were estimated using the cluster option [22] account-
ing for intra-nodular correlation.
Changes in Genotypic Frequencies
Hardy-Weinberg equilibrium was tested using the x
2 test, unless
the sample size was small. In this case, Fisher’s exact test was used.
Ivermectin selection in O. volvulus
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compared using Fisher’s exact test. To evaluate whether some
host covariates or village characteristics may have influenced the
heterozygosity of the worms, the association between heterozygous
status and the five main possible covariates quoted above was
assessed separately on pre- and post-treatment data, by multivar-
iate logistic regressions. Potential intra-nodule clustering was
accounted in the regression models.
Relationship between Genotype and Fertility of Female
Worms Before and After Treatment
Logistic regression models were used to analyze the independent
variables associated with the fertility of the female worms before
and after treatment. The dependent variable ‘‘fertility’’ was
defined, for this analysis, using two categories: no or low fertility
versus high fertility [18]. This choice is based on the fact that only
worms with mf have the possibility of having their progeny
transmitted, at the time of sampling, and this may be relevant to
the possible transmission of any ‘‘resistant’’ genotypes. However,
any treatment group effect on fertility status could be due to either
treatment frequency or to the fact that the worms were collected
three months after the last treatment in the three-monthly treated
groups (groups 2 and 4) and twelve months post-treatment in the
annual groups (groups 1 and 3). The possible covariates in the
model included the five host-related independent variables defined
above, and two other independent variables: the genotype of the
worm at the b-tubulin locus (homozygous versus heterozygous), and
the total number of males present in the nodule. Here again, the
intra-nodule clustering was considered in the logistic regressions.
The x
2 and Fisher’s exact test analyses were performed using
VassarStats (http://faculty.vassar.edu/lowry/VassarStats.html).
Results
A total of 73 patients provided one nodule at the outset of the trial
and one nodule after treatment. A total of 367 worms (248 females,
119 males) were isolated from the 73 nodules collected before
treatment, and 224 worms (153 females, 71 males) were extracted
from the 73 nodules provided by the same hosts after three years of
repeated treatment. Details on the numbers of worms analyzed in
the different treatment groups are given in Tables 1 and 2.
Study of the Independent Variables That Could Be
Associated with the Inability to Genotype the Worms for
the b-tubulin Gene
We previously showed, in a sample of 320 female worms
collected before treatment as part of the same trial, that the 90
worms that could not be genotyped for b-tubulin did not differ
significantly, with regard to several host independent variables,
from the 230 worms that could be genotyped [18]. Similar results
were obtained when comparing the 65 non-genotyped females to
the 183 genotyped ones, and the 63 non-genotyped males to the
Table 1. Number of Nodules and Worms Collected and Genotyped Before Ivermectin Treatment in 73 Patients Who Provided Pre-
and Post-Treatment Nodules.
Rx group No. Nod. Female worms Male worms
No.worms
(No./Nod.)
b-tubulin
(%) hsp60 (%) ARP (%)
No.
Phen.
No. worms
(No./Nod.)
b-tubulin
(%) hsp60 (%) ARP (%)
150*1 18 67 (3.72) 52 (77.6) 46 (68.7) 57 (85.1) 67 34 (1.89) 12 (35.3) 16 (47.1) 33 (97.1)
150*4 16 49 (3.06) 35 (71.4) 33 (67.3) 37 (75.5) 49 28 (1.75) 12 (42.9) 11 (39.3) 26 (92.9)
800*1 22 67 (3.05) 45 (67.2) 53 (79.1) 56 (83.6) 66 28 (1.27) 17 (60.7) 14 (50.0) 28 (100.0)
800*4 17 65 (3.82) 51 (78.5) 55 (84.6) 59 (90.8) 65 29 (1.71) 15 (51.7) 15 (51.7) 27 (93.1)
Total 73 248 (3.40) 183(73.8) 187 (75.4) 209 (84.2) 247 119 (1.63) 56 (47.1) 56 (47.1) 114 (95.8)
Rx group=treatment group (dose mg/kg * frequency per year); No. Nod.=number of nodules; No. worms=number of worms; No./Nod.=number of worms per nodule;
b-tubulin=number of worms genotyped for b-tubulin; hsp60=number of worms genotyped for hsp60; ARP=number of worms genotyped for acidic ribosomal
protein; No. Phen.=number of worms phenotyped for fecundity.
doi:10.1371/journal.pntd.0000072.t001
Table 2. Number of Nodules and Worms Collected and Genotyped After Ivermectin Treatment in 73 Patients Who Provided Pre-
and Post-Treatment Nodules.
Rx group No. Nod Female worms Male worms
No. worms
(No./Nod.)
b-tubulin
(%) hsp60 (%) ARP (%)
No.
Phen.
No. worms
(No./Nod.)
b-tubulin
(%) hsp60 (%) ARP (%)
150*1 18 41 (2.28) 32 (78.0) 24 (58.5) 31 (75.6) 39 22 (1.22) 5 (22.7) 10 (45.5) 22 (100.0)
150*4 16 35 (2.19) 21 (60.0) 17 (48.6) 28 (80.0) 34 15 (0.94) 4 (26.7) 5 (33.3) 12 (80.0)
800*1 22 47 (2.14) 27 (57.4) 28 (59.6) 39 (83.0) 45 23 (1.05) 13 (56.5) 10 (43.5) 22 (95.7)
800*4 17 30 (1.76) 18 (60.0) 20 (66.7) 26 (86.7) 29 11 (0.65) 4 (36.4) 4 (36.4) 11 (100.0)
Total 73 153 (2.10) 98 (64.1) 89 (58.2) 124 (81.0) 147 71 (0.97) 26 (36.6) 29 (40.8) 67 (94.4)
Rx group=treatment group (dose mg/kg * frequency per year); No. Nod.=number of nodules; No. worms=number of worms; No./Nod.=number of worms per nodule;
b-tubulin=number of worms genotyped for b-tubulin; hsp60=number of worms genotyped for hsp60; ARP=number of worms genotyped for acidic ribosomal
protein; No. Phen.=number of worms phenotyped for fecundity.
doi:10.1371/journal.pntd.0000072.t002
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people from whom nodules could be analyzed both before and
after treatment.
The proportion of female worms that could not be genotyped
for b-tubulin was significantly higher after treatment (respectively
26.2% and 35.9% before and after treatment; p=0.043). Among
the 153 female worms collected after treatment, 55 could not be
genotyped. According to multivariate logistic regression, the
‘‘genotyped’’ status was not associated with any of the five
covariates included in the analysis. The proportion of non-
genotyped male worms did not differ significantly before and after
treatment (respectively 52.9% and 63.4%; p=0.17). After
treatment, we observed that a significantly higher proportion of
male worms could be genotyped in the 800 mg/kg/year treatment
group (OR=3.97 (95% CI, 1.05–15.08); p=0.043) compared to
the standard group. None of the other independent variables
differed significantly between the genotyped and the non-
genotyped male worms. Taken together, these results do not
provide evidence of bias between the 45 non-genotyped and 26
genotyped male worms according to the tested covariates.
Genotypic Frequencies for the Heat Shock Protein 60
Gene
Male worms. Amongst the 56 pre-treatment male worms
that could be genotyped for this gene, the proportions of worms
showing AA, AG and GG genotypes were 8.9%, 32.1% and
59.0%, respectively. This gene was in Hardy-Weinberg
equilibrium before treatment. After treatment, among the 29
genotyped males, the corresponding proportions were 6.9%,
34.5% and 58.6%. Fisher’s exact test did not demonstrate any
significant difference in genotypic frequencies between pre- and
post-treatment male worms (p=0.99). It was not possible to
determine whether treatment frequency affected male worm hsp60
genotype after treatment because the sample size was too small.
Female worms. Amongst the 187 pre-treatment female
worms that could be genotyped, the proportions of AA, AG and
GG were, respectively, 9.1%, 35.3% and 55.6%. This gene was in
Hardy-Weinberg equilibrium before treatment. After treatment,
among the 89 genotyped females, the corresponding proportions
were 6.8%, 43.8% and 49.4%. Fisher’s exact test did not
demonstrate any significant difference in genotypic frequencies
between pre- and post-treatment female worms (p=0.37). It was
possible to pool the female worms based on frequency of treatment
because there were no significant differences between groups 1 and 3
before treatment (p=0.96) and after treatment (p=0.12), and
between the groups 2 and 4 before treatment (p=0.055) and after
treatment (p=0.40). There were no significant differences in the
hsp60 genotype frequencies between the pooled annual treatment
groups before and after treatment (p=0.11) and between the three-
monthly treatment groups before and after treatment (p=0.23).
Genotypic Frequencies for the Acidic Ribosomal Protein
Gene
Male worms. Amongst the 114 pre-treatment male worms
that could be genotyped for this gene, the proportions of worms
showing CC, CT and TT genotypes were 4.4%, 27.2% and
68.4%, respectively. After treatment, among the 67 genotyped
males, the corresponding proportions were 0%, 28.4% and 71.6%.
Fisher’s exact test did not demonstrate any significant difference in
genotypic frequencies between pre- and post-treatment male
worms (p=0.27). Hardy-Weinberg analysis was not conducted on
the acidic ribosomal protein gene because it has multiple copies in
eukaryoteswith copies occurring at different loci [21]. It was possible
to pool the male worms, in frequency of treatment groups, because
there were no significant differences between groups 1 and 3 before
treatment (p=0.47) and after treatment (p=0.09), and between
groups 2 and 4 before treatment (p=1) and after treatment
(p=0.59). There were no significant differences in ARP genotypes
frequencies between the pooled annual treatment groups before and
after treatment (p=0.51) and between the three-monthly treatment
groups before and after treatment (p=0.19).
Female worms. Amongst the 209 pre-treatment female
worms that could be genotyped, the proportions of CC, CT and
TT were, respectively, 0%, 89.0% and 11.0%. After treatment,
among the 124 genotyped females, the corresponding proportions
were 0.8%, 90.3% and 8.9%. Fisher’s exact test did not
demonstrate any change in genotype frequencies between pre-
and post-treatment female worms (p=0.38). It was possible to pool
the female worms in frequency of treatment groups because there
were no significant differences between groups 1 and 3 before
treatment (p=0.39) and after treatment (p=0.08), and between
groups 2 and 4 before treatment (p=0.50) and after treatment
(p=0.61). There were no significant differences in ARP genotype
frequencies between the pooled annual treatment groups before
and after treatment (p=0.59) and between the three-monthly
treatment groups before and after treatment (p=0.77).
Genotypic Frequencies for the b-tubulin Gene
Male worms. Amongst the 56 pre-treatment male worms
that could be genotyped, the proportions of homozygous allele
a (aa), heterozygotes (ab) and homozygous allele b (bb) were,
respectively, 92.9%, 5.4% and 1.8%. After treatment, among the
26 genotyped males, the corresponding proportions were 96.2%,
3.8% and 0%. No change in genotypic frequencies between pre-
and post-treatment male worms was found, using Fisher’s exact
test. Before treatment, the 56 males were in Hardy-Weinberg
equilibrium (Fisher’s exact test, p=0.99).
Female worms. Before treatment, there was no difference in
genotype frequency (x
2=0.036; p=0.98) between any of the
groups. The 183 females analyzed before treatment were not in
Hardy-Weinberg equilibrium (x
2=26.5; p,0.0001), with an
excess of homozygotes. Amongst the female worms, the treat-
ment led to an increase in the proportion of b-tubulin heterozy-
gous worms (Figure 1). The reduction in the proportion of
homozygous aa worms for b-tubulin was most marked in the
150 mg/kg three-monthly group (reduction rate in the proportion
of aa worms: 73.6%). We also observed the same pattern of
reduction in aa worms, though less dramatic, in the other treated
groups (21.9%, 49.3% and 50.0%, respectively, in groups 1, 3
and 4). Conversely, the frequency of heterozygotes increased
dramatically among the female worms collected in the group
treated at 150 mg/kg three-monthly and also markedly in the
other groups (x
2 test, p,10
211). It was possible to pool the female
worms in frequency of treatment groups because there were no
significant differences between groups 1 and 3 before treatment
(p=0.60) and after treatment (p=0.43), and between groups 2 and
4 before treatment (p=0.78) and after treatment (p=0.72). After
treatment, dose rate (150 or 800 mg/kg) per se did not have an
effect on b-tubulin genotype frequency. However, there was
a significant difference (Fisher’s exact test, p=0.047) between the
pooled annual treatment groups with respectively 44.1%, 55.9%
and 0% of aa, ab and bb and the three-monthly treatment groups
with respectively 25.6%, 69.2% and 5.1% of aa, ab and bb. Hence
treatment frequency, or the total number of treatments given
within the three years, did have a significant effect on the b-tubulin
genotype frequencies in the female worms, recorded after
treatment (Figure 1).
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Before treatment, b-tubulin heterozygous status was not influenced
byageofhost,totalnumberoffemalesinthe nodule,totalnumberof
palpable nodulesorCMFLinthe villageof residence(Table 3).After
treatment, none of the tested covariates was significantly associated
with the b-tubulin heterozygous status, except the fact of living in
a village with a CMFL between 41 and 60 mf/ss. This weak associa-
tion (OR=6.24(95%CI,1.09–35.59);p=0.039) mightindicate that
the probability of being heterozygous was higher in the villages
where infection rates were rather high (Table 4). The probability of
being heterozygous tended to be higher in the groups treated three-
monthly. Even if this was not significant in the analysis taking into
account the various groups separately, this trend is consistent with
the results presented above comparing the pooled annual treatment
groups and the pooled three-monthly treatment groups.
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Figure 1. b-tubulin Genotype of Female Worms. b-tubulin genotype of female worms, that could be genotyped, before and after different doses
of ivermectin. IVM=ivermectin treatment. { Pooled by treatment frequency.
doi:10.1371/journal.pntd.0000072.g001
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Before treatment, the homozygote genotype was the only
independent variable associated with a high fertility phenotype
(p,0.002) (Table 5). After treatment, high fertility of the worms
was still associated with the homozygous genotype (p=0.035). In
addition, high fertility of the worms was more likely to be observed
amongst younger patients (p=0.018). Finally, high fertility in the
worms was more apparent in nodules containing higher numbers
of male worms (p=0.030) (Table 6).
As the intervals between the last IVM treatment and nodulec-
tomy in the three-monthly groups and the annual treatment
groups were different, they have also been considered separately
(Figure 2). Twelve months after the last IVM treatment, analysis of
the fertility (non- and low fertility versus full fertility) in relation to
genotype showed that the b-tubulin homozygous worms remained
more fertile than the heterozygous worms (x
2=11.06, p,0.001;
Figure 2). Because the sample size was small, we did not perform
an analysis on the data collected on the three-monthly groups
(samples collected three months after the last IVM treatment;
groups 2 and 4). However, the figure shows that the proportion of
fully fertile worms was higher in the homozygous worms (42%
compared with 24%), but both genotype groups showed a similar
proportion of non-fertile worms (50% and 48%, respectively, for
the homozygous and heterozygous parasites).
Table 3. Analysis of the Relationship of b-tubulin Genotype
with Patient and Parasitological Independent Variables Before
Treatment.
N=183 female worms OR 95% CI p
Age of patient 0.97 0.93–1.00 0.081
No. females/nod. 0.94 0.73–1.21 0.629
CMFL 41–60 mf/ss 0.81 0.13–5.15 0.819
CMFL 61–70 mf/ss 1.93 0.44–8.49 0.385
CMFL 71–114 mf/ss 0.44 0.06–3.15 0.413
No. nod. 1994 1.00 0.81–1.22 0.976
Odds ratios (OR) and 95% confidence intervals (95% CI) for logistic regression of
heterozygote status (vs. homozygote) of worms collected before ivermectin
treatment on four independent variables. No. females/nod.=total number of
females in the nodule; No. nod. 1994=total number of palpable nodules in
1994; CMFL=Community Microfilarial Load (reference category: 10–
40 microfilariae per skin snip (mf/ss)).
doi:10.1371/journal.pntd.0000072.t003
Table 4. Analysis of the Relationship of b-tubulin Genotype
with Patient and Parasitological Independent Variables After
Treatment.
N=98 female worms OR 95% CI p
150 mg/kg three-monthly 2.22 0.39–12.65 0.370
800 mg/kg yearly 0.93 0.22–3.94 0.923
800 mg/kg three-monthly 1.68 0.23–12.15 0.609
Age of patient 1.00 0.94–1.04 0.691
No. females/nod 0.83 0.57–1.23 0.356
CMFL 41–60 mf/ss 6.24 1.09–35.59 0.039
CMFL 61–70 mf/ss 4.44 0.91–21.54 0.065
CMFL 71–114 mf/ss* - - -
No. nod. 1994 0.88 0.68–1.13 0.305
Odds ratios (OR) and 95% confidence intervals (95% CI.) for logistic regression
of heterozygote status (vs. homozygote) of worms collected after ivermectin
treatment on five independent variables. No. females/nod.=total number of
females in the nodule; No. nod. 1994=total number of palpable nodules in
1994; CMFL=Community Microfilarial Load (reference category: 10–
40 microfilariae per skin snip (mf/ss)). Reference category for treatment group:
150 mg/kg yearly.
*All worms from villages with CMFL 71–114 mf/ss were heterozygotes;
consequently, the highest CMFL category was not used for the estimation of
other independent variables.
doi:10.1371/journal.pntd.0000072.t004
Table 5. Analysis of the Relationship of Parasite Fertility with
b-tubulin Genotype, Patient and Parasitological Independent
Variables Before Treatment.
N=183 female worms OR 95% CI p
Genotype=homozygote 3.71 1.59–8.70 0.002
Age of patient 1.00 0.97–1.04 0.940
No. females/nod. 0.85 0.70–1.02 0.085
CMFL 41–60 mf/ss 0.69 0.15–3.23 0.635
CMFL 61–70 mf/ss 1.12 0.25–5.09 0.879
CMFL 71–114 mf/ss 1.93 0.40–9.37 0.415
No. nod. 1994 0.97 0.86–1.10 0.633
No. males 1.10 0.76–1.60 0.599
Odds ratios (OR) and 95% confidence intervals (95% CI) for logistic regression of
full fertility (vs. low- or non-fertility) of worms collected before ivermectin
treatment on six independent variables. Reference category for genotype:
heterozygosity for b-tubulin gene. No. females/nod.=total number of females
in the nodule. No. nod. 1994=total number of palpable nodules in 1994. No.
males=number of males in the nodule. CMFL=Community Microfilarial Load
(reference category: 10–40 microfilariae per skin snip (mf/ss)).
doi:10.1371/journal.pntd.0000072.t005
Table 6. Analysis of the Relationship of Parasite Fertility with
b-tubulin Genotype, Patient and Parasitological Independent
Variables After Treatment.
N=98 female worms OR 95% CI p
Genotype=homozygote 3.90 1.10–13.79 0.035
150 mg/kg three-monthly 1.71 0.27–10.60 0.566
800 mg/kg yearly 0.78 0.20–3.14 0.731
800 mg/kg three-monthly 2.47 0.42–14.58 0.320
Age of patient 0.94 0.89–0.99 0.018
No. females/nod. 1.10 0.76–1.76 0.506
CMFL 41–60 mf/ss 0.33 0.04–3.21 0.342
CMFL 61–70 mf/ss 1.59 0.20–12.47 0.657
CMFL 71–114 mf/ss 0.57 0.06–5.18 0.619
No. nod. 1994 1.09 0.84–1.40 0.522
No. males 2.38 1.09–5.21 0.030
Odds ratios (OR) and 95% confidence intervals (95% CI) for logistic regression of
full fertility (vs. low- or non-fertility) of worms collected after ivermectin
treatment on seven independent variables. Reference category for genotype:
heterozygosity for b-tubulin gene. Reference category for treatment group:
150 mg/kg yearly. No. females/nod.=total number of females in the nodule; No.
nod. 1994=total number of palpable nodules in 1994; No. males=number of
males in the nodule; CMFL=Community Microfilarial Load (reference category:
10-40 microfilariae per skin snip (mf/ss)).
doi:10.1371/journal.pntd.0000072.t006
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With the implementation of the onchocerciasis control pro-
grammes, an increasing proportion of people in endemic areas
have received community-directed treatment with IVM on
a regular basis. Even though children under 5 years of age and
pregnant women are excluded from mass treatment, a high
proportion of the parasite population, in control areas, is under
treatment. As a consequence, and because most of the parasite
population is in the human hosts rather than in the vector, only
a relatively small proportion of the O. volvulus population is likely to
be in refugia (not exposed to the drug) at the time of treatment.
Thus, selection pressure for any IVM resistance alleles is expected
to be high in O. volvulus [7].
Parasitological and epidemiological evidence of ivermectin
resistance in O. volvulus populations has been reported in Ghana
[11]. Selection on the b-tubulin gene following repeated IVM
treatment of people infected with O. volvulus, compared with
parasites from IVM-naı ¨ve people has been found in Ghana
[16,17]. Because gene selection is the first step in the development
of drug resistance, it is important to assess genetic change in
a population of parasites exposed to selection pressure.
Our study of the possible effects of IVM on the genetic structure
of an O. volvulus population is unique in several respects. We
analyzed nodules from the same patients before and after three
years of IVM treatment at different treatment frequencies, dose
rates, and with complete knowledge of the number of IVM
treatments. To our knowledge, this has never been done in past
investigations of the effect of IVM on genetic selection in human
parasitic nematodes. In the study area, because there was no
vector control and only a small proportion of the population living
in the area was treated during the trial, the force of infection
probably did not decrease during the trial [3].
The main finding, that IVM treatment selected for hetero-
zygotes at the b-tubulin locus and that this selection was
dependent on the number of doses, raises interesting questions
in view of the fact that this gene has been linked with IVM
resistance in another parasitic nematode [17] and the recent
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Figure 2. Relationship between Female Worm Fertility and b-tubulin Genotype in Relation to Treatment Group. Relationship between
female worm fertility and b-tubulin genotype (homozygous or heterozygous) in relation to treatment group (annual versus three-monthly
treatments, corresponding also to 4 versus 13 treatment rounds within three years). IVM=ivermectin treatment; FF=fully fertile; F=low fertility;
NF=not fertile.
doi:10.1371/journal.pntd.0000072.g002
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period over which the IVM treatment-associated genetic change in
b-tubulin occurred was short (1994 to 1997). It takes about 1 year
from microfilarial birth until an adult worm commences pro-
duction of the next generation of microfilaria. The observed
genetic changes are dramatic, given the time period and the
generation interval, and could result from differential mortality of
existing adult worms and possibly a differential establishment of
new worms, dependent on the worm genotype and tolerance to
the drug pressure. These possible selective events will require
further investigation. IVM might be more toxic to the more fertile
female worms, which were previously found to be homozygous at
the b-tubulin locus [18], as a result of the effect of IVM in
preventing the release of microfilariae from the uterus and the
subsequent degeneration of these trapped microfilariae.
The main limitation of the present study was that some samples
could notbegenotyped. As suggestedinthepreviouspaper [18]with
samplesfrom thesametrial [3],there areseveral explanations for the
difficulty in genotyping some of the adult worms. The nodules had
been stored in a dessicating fixative,at room temperature, for several
years before they were digested and the DNA extracted. It is likely
that some of the worms that could not be genotyped were dead or
moribund at the time that the nodules were harvested. The DNA of
dead or moribundparasites may have beendegradedorfragmented,
and difficult to amplify. Dead O.volvulusare not rapidly resorbed and
can be readily found in nodules [20,23]. In the study area before
treatment, 15.2% of adult female worms found in nodules were
moribund or dead [24]. After treatment, the proportion of non-
genotypedparasiteswashigher(p=0.024),whichcouldbeduetothe
macrofilaricidal effect of IVM [3,25,26].
Very similar numbers of worms were genotyped for b-tubulin
and for hsp60 before and after treatment. Most of the worms that
could not be genotyped for the acidic ribosomal protein gene
could also not be genotyped for b-tubulin. However, a higher
proportion of the acidic ribosomal protein gene was genotyped
compared with the b-tubulin and the hsp60 genes. The fact that
acidic ribosomal protein has many gene copies in eukaryotic genomes
[21], whereas b-tubulin and hsp60 typically do not occur with
multiple gene copies, could explain the difference in the ease of
genotyping the acidic ribosomal protein gene compared with the b-
tubulin and hsp60 genes.
Notwithstanding these likely reasons why some worms could not
be genotyped, we have performed several analyses to evaluate
whether the population of those worms that could not be genotyped
was similar to the population of worms that were genotyped. We
showed that the two populations did not differ according to various
external covariates (host age, CMFL level, etc.).
The female worms were not dissected into different tissues, but
each worm was analyzed as a single entity. Any microfilarial DNA
present within the female worm would be included in the DNA
analysis of the female worm, and so the b-tubulin genotype
frequencies of the female worms could have resulted from
microfilarial/embryo DNA contamination within the female
worm. Such daughter microfilariae/embryos would have half of
their DNA derived from that mother worm and thus reflect the
genome of the mother worm. Any contribution from male worms
to the assessed genotype of a female worm via the daughter
microfilaria/embryos contained within the female worm, would, if
a significant effect, tend to increase the probability that female
worm genotypes would be seen as heterozygotes. In fact, in the
female worms before treatment there was an excess of homo-
zygotes, indicating that any contribution from male worms to the
genotype assessed in the female worms was not significant. Given
the low frequency of the ‘‘b’’ allele in the male worms before and
after treatment, the increase in the frequency of ‘‘ab’’ hetero-
zygotes in the female worms, following treatment, could not be
accounted for by male worm contamination via microfilaria/
embryos contained within the female worm.
Finally, the frequency of ‘‘ab’’ heterozygotes was greater in the
three-monthly treatment groups (69%) than in the annual treatment
groups (56%) and the pre-treatment sample (21%). IVM treatment
reduces fertility so that if microfilarial/embryonic DNA were con-
tributing to the assessment of DNA of the female worms, treatment
should have decreased, rather than increased, the proportion of
female worms that appeared as heterozygotes. For these reasons we
do not believe that microfilarial/embryonic DNA within the female
worms had any significant influence on the observed genotype
frequencies for b-tubulin observed in the female worms.
One possible explanation for the apparent IVM selection on b-
tubulin in the female worms is the existence of a null allele (an allele
that is not being detected by the method used) that could be
distorting the genotype frequencies determined. Previously, we have
found that freshly frozen O. volvulus samples always amplified readily
with the same b-tubulin primers as have been used in this study [17]
suggestingthatnonullalleleexists,usingtheproceduresfollowed,for
b-tubulin in O. volvulus. We do not believe that a null allele exists to
affect the genotype frequencies. Furthermore, even if it did exist, it
could not account for the change in genotype frequencies resulting
from IVM treatment. We can conclude that the observed change in
b-tubulin genotype frequency with treat-
ment isgeneticselectionashasbeenseenpreviouslyinO.volvulusthat
have been obtained from people who have been repeatedly treated
with IVM and also observed in IVM-resistant H. contortus [16,17].
One of the main findings of the study is that female worms,
homozygous for b-tubulin, were more fertile than heterozygote
female worms. A similar difference in fertility before treatment was
reported previously [18]. Homozygous worms, in the patients
treated annually and collected twelve months after the last IVM
treatment, also had higher fertility than heterozygotes. However,
this difference decreased if the worms were collected three months
after 13 three-monthly IVM treatments, at a time when the
embryostatic effect of IVM is normally still apparent. The results
observed three months after IVM (Figure 2) could be due to
a combination of innate differences in fertility between homozy-
gous and heterozygous worms and the relative effects of IVM on
embryostasis in the different genotypes. If the fertility disadvantage
of heterozygotes tends to disappear when the parasite is under
strong IVM pressure, this could have implications for parasite
transmission and possible resistance selection. It would be
interesting to study, perhaps in Caenorhabditis elegans, how poly-
morphism in b-tubulin may affect the fertility of nematodes.
Before treatment, hsp60 gene was in Hardy-Weinberg equilib-
rium in the female and male worm populations as well as for the
b-tubulin gene in the male worm population. The acidic ribosomal
protein gene normally has multiple gene copies [21], which means
that there are multiple loci in the genome. For this reason, it is
inappropriate to apply a Hardy-Weinberg equilibrium test, as used
on a single locus. The b-tubulin gene was not in Hardy-Weinberg
equilibrium in the female worms, as there was an excess of
homozygotes in this population. Various assumptions are required
for Hardy-Weinberg equilibrium including random mating. Non-
random mating could occur in the O. volvulus population and be
due to inbreeding, positive assortative mating or a subpopulation
structure [27]. The inbreeding coefficient F, which represents the
proportional loss of heterozygosity due to inbreeding, was
calculated for the population of 73 patients, based on the b-
tubulin data, to be 0.41. This index of inbreeding is moderately
high and has implications not only for Hardy-Weinberg
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population [28]. Inbreeding could be explained by the fact that
vectors transmitting to the study population were living in the local
area and tend to bite people from the same community.
It is of interest that the FIT (inbreeding coefficient within
a subpopulation) for Wuchereria bancrofti microfilariae, a closely
related human filarial nematode, was calculated on the basis of b-
tubulin genotype frequencies to be 0.44 [29]. However, other
processes may be involved. An assortative mating coefficient R
(which could include inbreeding) was calculated [27] to be 0.54.
The higher fertility of the female b-tubulin homozygote ‘‘aa’’
worms, when compared with the female heterozygote ‘‘ab’’
worms, could be consistent with positive assortative mating if the
likelihood that a worm will mate is associated with the female
worm’s fecundity. It is known that male O. volvulus migrate
between nodules and may be attracted by the fully fertile females
(predominantly homozygous). Subpopulation structure could also
explain the Hardy-Weinberg disequilibrium. Because the samples
were collected in a forest/savannah transition zone, the worms
could belong either to a savannah, or to forest or mixed forest/
savannah strains. Subpopulations can result from environmental
segregation, inbreeding and/or positive assortative mating.
Finally, it is possible that in the absence of IVM treatment, the
b-tubulin heterozygote female worms die faster than the homozy-
gote female worms. Differential mortality between the genotypes
could also affect Hardy-Weinberg equilibrium.
The selection for the b-tubulin heterozygote ‘‘ab’’, found in female
worms after IVM treatment, was more important in the worms
exposed to IVM every three months compared with the worms
exposed to IVM annually. This difference could be due to either the
total number of treatments or to the interval between treatments.
These are important points for the onchocerciasis control pro-
grammes because semi-annual or more frequent treatments are
ongoing in some areas and under consideration in other areas. An
increaseintreatmentfrequencymightincreasetheselectionpressure.
No selection was demonstrated in the male worm population
after treatment, during the three-year study period. This result
suggests that the female worms are more susceptible to IVM
pressure than the males and could reflect an increased IVM-
induced mortality in female worms that are homozygous at the b-
tubulin locus. From the Gardon et al. trial in Cameroon [3], it is
possible to estimate the relative proportional decrease in male and
female parasites due to IVM treatment over the study period. This
amounts to 13.5% and 27.5%, respectively. If the male parasites
are less affected by the treatment, the genotype frequencies in the
male population would only change significantly following trans-
mission and subsequent infection by progeny of the parasites
under selection. Given that it takes about one year to complete the
life cycle of O. volvulus, in this situation it would take longer for
IVM selection to influence male worm genotype frequencies. It is
interesting in this regard that in Brugia malayi, sex-dependent
expression in a possible IVM receptor has been demonstrated
[30]. The putative glutamate-gated chloride (GluCl) channel gene,
AF118554, was estimated to be expressed at a 24.3-fold higher
level in female worms compared with male worms. As GluCl is
thought to be the main target of IVM [31], one could speculate
that the effect of IVM might be greater in female than male
worms. This might explain why O. volvulus male worms seem to be
less susceptible to IVM and thus less rapidly selected than female
worms, so that in the short three-year time interval of this study no
significant change in b-tubulin genome frequency was seen in the
male worms. However, selection on b-tubulin in male O. volvulus has
been found when parasite populations were exposed over 6 or
more years to IVM [16,17].
There may also be an IVM-induced mortality of the incoming
larvae or pre-adult stages of the parasites, with the homozygous
worms being more sensitive to repeated treatment than the
heterozygote parasites. An effect of IVM on the pre-adult stages of
O. volvulus has been suggested [32] and demonstrated in results
obtained on the bovine parasite Onchocerca ochengi [33].
Today, intestinal trichostrongylid nematodes of livestock are
commonly strongly resistant to IVM, and the development of IVM
resistance can occur rapidly in these nematode parasites,
sometimes in less than three years [34]. However, trichostrongylid
nematodes and filarial nematodes have different biology. As the
generation time is shorter in trichostrongylid nematodes than in
filarial nematodes, resistance selection would be expected to take
longer to be manifested in filarial worms. In contrast to soil
transmitted nematodes, filariae have no free-living stages and most
of the population of the nematode occurs in the human host, so
that refugia is likely to be low in a community under treatment. As
a result, selection pressure for resistance to develop could be high
in human filarial nematodes under intensive drug treatment [7].
Conclusion
IVM has been used since the late 1980s, and more than 400
million doses have been distributed in Africa [4]. It remains the
only safe drug for community treatment of onchocerciasis. Our
results clearly show a genetic selection in O. volvulus caused by
repeated IVM treatment. Since the parasites were collected before
and after treatment from the same patients, these results cannot be
explained as differences arising from different host populations
being sampled. These results, together with other evidence of
genetic selection and reports of sub-optimal responses to IVM,
provide a warning that selection for IVM resistance could be
occurring in some populations of O. volvulus.
In view of these results, it is imperative that field studies be
undertaken to characterize all treatment responses to IVM in O.
volvulus,coupled tofurthergeneticanalysis,inordertoconfirmor not
the possible emergence of IVM resistance. Such longitudinal studies,
which would look at the repopulation of the skin of treated people by
mf,shouldbeundertaken withoutdelayifthebenefitsthat havebeen
achieved bytheonchocerciasiscontrolprogrammesarenottobe lost
as a result of the spread of IVM resistance in O. volvulus.
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